Clinical Trials Logo

Resectable Carcinoma clinical trials

View clinical trials related to Resectable Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05802407 Recruiting - Pancreatic Cancer Clinical Trials

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

MAP-02
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: - prognostic value of baseline MRD; - the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.

NCT ID: NCT04736485 Active, not recruiting - Clinical trials for Resectable Carcinoma

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

GASPAR
Start date: June 28, 2021
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)

NCT ID: NCT04554771 Active, not recruiting - Clinical trials for Esophageal Adenocarcinoma

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

BASALT
Start date: January 27, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in patients with adenocarcinoma of the esophagus or gastroesophageal junction with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive blood-borne marker of stromal activation.